Comparative Analysis of Chemotherapy and Epidermal Growth Factor Receptor (EGFR)-Targeted Treatment Strategies in Never-Smoker Patients with Advanced Non-Small Cell Lung Cancer

Lung cancer is the most common cancer worldwide and the leading cause of cancer-related death. While smoking is a major risk factor, an increasing number of people who have never smoked are developing lung cancer. This has raised concern among doctors and researchers. The most common type of lung cancer in never-smokers is called non-small cell lung cancer (NSCLC), which is a broad group of lung cancers that often behave differently from one patient to another. Many people with this condition have a poor outlook, meaning their disease is difficult to treat successfully.

In many never-smokers, lung cancer growth is driven by changes in a protein called the epidermal growth factor receptor (EGFR). This protein helps control how cells grow and divide. Medicines known as epidermal growth factor receptor inhibitors are designed to block this signal and slow cancer growth. Two such medicines, erlotinib and gefitinib, have improved outcomes for some patients. However, not all patients benefit in the same way, and some experience more side effects than others. At present, it is not fully understood why these differences occur.

In this research project, we will use existing data from two completed clinical trials to better understand how patients respond to EGFR inhibitor treatments.

First, we will describe who took part in the studies, including basic characteristics such as age and sex, as well as clinical information like disease stage, treatment outcomes, and side effects. We will also review molecular information from the tumor, such as changes in genes or proteins, as these can help explain why a cancer develops and how it may respond to treatment.

Next, we will compare patients across the two studies to look for patterns in how well treatments worked and how safe they were. We will pay particular attention to groups of patients with specific EGFR changes, as these may respond differently to treatment.

If information on how the body processes the drugs is available, we will also study differences in drug levels between patients. This type of information, known as pharmacokinetics (how a drug is absorbed, distributed, and cleared from the body), may help explain why some patients respond better or experience more side effects than others.

Overall, this research will improve understanding of why responses to epidermal growth factor receptor inhibitors vary between individuals. The findings may help guide future research and support more personalized treatment approaches for people with lung cancer.